ATE291923T1 - Veränderter faktor viii - Google Patents

Veränderter faktor viii

Info

Publication number
ATE291923T1
ATE291923T1 AT00932530T AT00932530T ATE291923T1 AT E291923 T1 ATE291923 T1 AT E291923T1 AT 00932530 T AT00932530 T AT 00932530T AT 00932530 T AT00932530 T AT 00932530T AT E291923 T1 ATE291923 T1 AT E291923T1
Authority
AT
Austria
Prior art keywords
factor viii
amino acid
altered factor
antibodies
modified
Prior art date
Application number
AT00932530T
Other languages
English (en)
Inventor
John S Lollar
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE291923T1 publication Critical patent/ATE291923T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
AT00932530T 1999-05-20 2000-05-16 Veränderter faktor viii ATE291923T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/315,179 US6376463B1 (en) 1992-04-07 1999-05-20 Modified factor VIII
PCT/US2000/013541 WO2000071141A1 (en) 1999-05-20 2000-05-16 Modified factor viii

Publications (1)

Publication Number Publication Date
ATE291923T1 true ATE291923T1 (de) 2005-04-15

Family

ID=23223252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932530T ATE291923T1 (de) 1999-05-20 2000-05-16 Veränderter faktor viii

Country Status (12)

Country Link
US (2) US6376463B1 (de)
EP (1) EP1200105B1 (de)
JP (1) JP3964622B2 (de)
AT (1) ATE291923T1 (de)
AU (1) AU765442B2 (de)
CA (1) CA2374675C (de)
CY (1) CY1110360T1 (de)
DE (1) DE60019122T2 (de)
ES (1) ES2238284T3 (de)
HK (1) HK1043543A1 (de)
PT (1) PT1200105E (de)
WO (1) WO2000071141A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
EP1351986A2 (de) * 2001-01-12 2003-10-15 The American National Red Cross Verfahren und zusammensetzungen zur verminderung von heparansulfatproteoglykan-vermittelter entfernung von faktor viii
EP1572889B1 (de) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
EP1456235A4 (de) * 2001-11-30 2005-08-17 Univ Emory Varianten der c2-domäne des faktors viii
EP1596887B1 (de) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii-konjugate
MXPA05011922A (es) * 2003-05-07 2006-02-17 Pfizer Prod Inc Ligandos del receptor de cannabinoides y sus usos.
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005046583A2 (en) * 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
ES2449044T3 (es) 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
LT3130601T (lt) * 2004-11-12 2020-09-10 Bayer Healthcare Llc Į vietą nukreipta fviii modifikacija
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
US8183345B2 (en) * 2007-11-01 2012-05-22 University Of Rochester Recombinant factor VIII having reduced inactivation by activated protein C
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
EP2742949A1 (de) * 2009-11-13 2014-06-18 Puget Sound Blood Center Faktor-VIII-B-Zellen-Epitopvarianten mit reduzierter Immunogenität
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
MY165089A (en) 2010-11-05 2018-02-28 Baxalta Inc A new variant of antihemophilic factor viii having increased specific activity
EP2717898B1 (de) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Gerinnungsfördernde verbindungen und anwendungsverfahren dafür
EA029045B1 (ru) 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
KR102212098B1 (ko) 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
SG11201404885RA (en) 2012-02-15 2014-09-26 Amunix Operating Inc Factor viii compositions and methods of making and using same
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
SG11201500045RA (en) 2012-07-11 2015-02-27 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (de) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
WO2014089541A2 (en) 2012-12-07 2014-06-12 Haplomics, Inc. Factor viii mutation repair and tolerance induction
EA201890671A1 (ru) 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
WO2014209942A1 (en) 2013-06-24 2014-12-31 Weidong Xiao Mutant factor viii compositions and methods
CN113831415A (zh) 2013-06-28 2021-12-24 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
EP3875106A1 (de) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
BR112016015512B1 (pt) 2014-01-10 2023-12-19 Bioverativ Therapeutics Inc Proteína quimérica, composição farmacêutica e seus usos
EP3114138B1 (de) 2014-03-05 2021-11-17 Pfizer Inc. Verbesserte muteine von gerinnungsfaktor viii
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
WO2022211791A1 (en) 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
WO1995018829A1 (en) 1994-01-07 1995-07-13 Novo Nordisk A/S Factor viii derivatives
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität

Also Published As

Publication number Publication date
CY1110360T1 (el) 2012-05-23
JP3964622B2 (ja) 2007-08-22
WO2000071141A1 (en) 2000-11-30
CA2374675A1 (en) 2000-11-30
DE60019122D1 (de) 2005-05-04
PT1200105E (pt) 2005-06-30
EP1200105B1 (de) 2005-03-30
JP2003508019A (ja) 2003-03-04
US7033791B2 (en) 2006-04-25
AU765442B2 (en) 2003-09-18
EP1200105A1 (de) 2002-05-02
ES2238284T3 (es) 2005-09-01
AU5023700A (en) 2000-12-12
EP1200105A4 (de) 2003-04-16
US20030166536A1 (en) 2003-09-04
US6376463B1 (en) 2002-04-23
CA2374675C (en) 2012-04-03
HK1043543A1 (en) 2002-09-20
DE60019122T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
ATE291923T1 (de) Veränderter faktor viii
DK1280540T3 (da) Modificeret faktor VIII
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE60001255T2 (de) Zusammensetzung zur Behandlung von Polyesterfaser
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
ATE241640T1 (de) Fusidinsäure-derivate
DE69911502D1 (de) Verfahren zur Behandlung von Kunststoffen auf mechanochemischem Weg
ATE226443T1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200105

Country of ref document: EP